BACKGROUND: As second-line antiretroviral treatment (ART) becomes more accessible in resource-limited settings (RLS), the need for more affordable monitoring tools such as point-of-care viral load assays and simplified genotypic HIV drug resistance (HIVDR) tests increases substantially. The prohibitive expenses of genotypic HIVDR assays could partly be addressed by focusing on a smaller region of the HIV reverse transcriptase gene (RT) that encompasses the majority of HIVDR mutations for people on ART in RLS. In this study, an in silico analysis of 125,329 RT sequences was performed to investigate the effect of submitting short RT sequences (codon 41 to 238) to the commonly used virco®TYPE and Stanford genotype interpretation tools. RESULTS: Pair-wise comparisons between full-length and short RT sequences were performed. Additionally, a non-inferiority approach with a concordance limit of 95% and two-sided 95% confidence intervals was used to demonstrate concordance between HIVDR calls based on full-length and short RT sequences.The results of this analysis showed that HIVDR interpretations based on full-length versus short RT sequences, using the Stanford algorithms, had concordance significantly above 95%. When using the virco®TYPE algorithm, similar concordance was demonstrated (>95%), but some differences were observed for d4T, AZT and TDF, where predictions were affected in more than 5% of the sequences. Most differences in interpretation, however, were due to shifts from fully susceptible to reduced susceptibility (d4T) or from reduced response to minimal response (AZT, TDF) or vice versa, as compared to the predicted full RT sequence. The virco®TYPE prediction uses many more mutations outside the RT 41-238 amino acid domain, which significantly contribute to the HIVDR prediction for these 3 antiretroviral agents. CONCLUSIONS: This study illustrates the acceptability of using a shortened RT sequences (codon 41-238) to obtain reliable genotype interpretations by virco®TYPE and Stanford algorithms. Implementation of this simplified protocol could significantly reduce the cost of both resistance testing and ARV treatment monitoring in RLS.
BACKGROUND: As second-line antiretroviral treatment (ART) becomes more accessible in resource-limited settings (RLS), the need for more affordable monitoring tools such as point-of-care viral load assays and simplified genotypic HIV drug resistance (HIVDR) tests increases substantially. The prohibitive expenses of genotypic HIVDR assays could partly be addressed by focusing on a smaller region of the HIV reverse transcriptase gene (RT) that encompasses the majority of HIVDR mutations for people on ART in RLS. In this study, an in silico analysis of 125,329 RT sequences was performed to investigate the effect of submitting short RT sequences (codon 41 to 238) to the commonly used virco®TYPE and Stanford genotype interpretation tools. RESULTS: Pair-wise comparisons between full-length and short RT sequences were performed. Additionally, a non-inferiority approach with a concordance limit of 95% and two-sided 95% confidence intervals was used to demonstrate concordance between HIVDR calls based on full-length and short RT sequences.The results of this analysis showed that HIVDR interpretations based on full-length versus short RT sequences, using the Stanford algorithms, had concordance significantly above 95%. When using the virco®TYPE algorithm, similar concordance was demonstrated (>95%), but some differences were observed for d4T, AZT and TDF, where predictions were affected in more than 5% of the sequences. Most differences in interpretation, however, were due to shifts from fully susceptible to reduced susceptibility (d4T) or from reduced response to minimal response (AZT, TDF) or vice versa, as compared to the predicted full RT sequence. The virco®TYPE prediction uses many more mutations outside the RT 41-238 amino acid domain, which significantly contribute to the HIVDR prediction for these 3 antiretroviral agents. CONCLUSIONS: This study illustrates the acceptability of using a shortened RT sequences (codon 41-238) to obtain reliable genotype interpretations by virco®TYPE and Stanford algorithms. Implementation of this simplified protocol could significantly reduce the cost of both resistance testing and ARV treatment monitoring in RLS.
Authors: Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Gunthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2009-12
Authors: Bart Winters; Elke Van Craenenbroeck; Koen Van der Borght; Pierre Lecocq; Jorge Villacian; Lee Bacheler Journal: J Virol Methods Date: 2009-08-03 Impact factor: 2.014
Authors: David M Moore; Anna Awor; Robert Downing; Jonathan Kaplan; Julio S G Montaner; John Hancock; Willy Were; Jonathan Mermin Journal: J Acquir Immune Defic Syndr Date: 2008-12-15 Impact factor: 3.731
Authors: Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes Journal: Clin Infect Dis Date: 2008-05-15 Impact factor: 9.079
Authors: Steven J Reynolds; Gertrude Nakigozi; Kevin Newell; Anthony Ndyanabo; Ronald Galiwongo; Iga Boaz; Thomas C Quinn; Ron Gray; Maria Wawer; David Serwadda Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Carole L Wallis; John W Mellors; Willem D F Venter; Ian Sanne; Wendy Stevens Journal: J Acquir Immune Defic Syndr Date: 2010-04-01 Impact factor: 3.731
Authors: Mina C Hosseinipour; Joep J G van Oosterhout; Ralf Weigel; Sam Phiri; Debbie Kamwendo; Neil Parkin; Susan A Fiscus; Julie A E Nelson; Joseph J Eron; Johnstone Kumwenda Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Awachana Jiamsakul; Romanee Chaiwarith; Nicolas Durier; Sunee Sirivichayakul; Sasisopin Kiertiburanakul; Peter Van Den Eede; Rossana Ditangco; Adeeba Kamarulzaman; Patrick C K Li; Winai Ratanasuwan; Thira Sirisanthana Journal: J Med Virol Date: 2015-07-17 Impact factor: 2.327
Authors: Susan C Aitken; Michelle Bronze; Carole L Wallis; Lieven Stuyver; Kim Steegen; Sheila Balinda; Cissy Kityo; Wendy Stevens; Tobias F Rinke de Wit; Rob Schuurman Journal: J Clin Microbiol Date: 2013-03-27 Impact factor: 5.948
Authors: Koen Van der Borght; Elke Van Craenenbroeck; Pierre Lecocq; Margriet Van Houtte; Barbara Van Kerckhove; Lee Bacheler; Geert Verbeke; Herman van Vlijmen Journal: BMC Bioinformatics Date: 2011-10-03 Impact factor: 3.169
Authors: Michelle Bronze; Kim Steegen; Carole L Wallis; Hans De Wolf; Maria A Papathanasopoulos; Margriet Van Houtte; Wendy S Stevens; Tobias Rinke de Wit; Lieven J Stuyver Journal: PLoS One Date: 2012-04-09 Impact factor: 3.240
Authors: Awachana Jiamsakul; Rami Kantor; Patrick C K Li; Sunee Sirivichayakul; Thira Sirisanthana; Pacharee Kantipong; Christopher K C Lee; Adeeba Kamarulzaman; Winai Ratanasuwan; Rossana Ditangco; Thida Singtoroj; Somnuek Sungkanuparph Journal: BMC Res Notes Date: 2012-10-24